1. AB0509 Kzr-616, a selective inhibitor of the immunoproteasome, shows a promising safety and target inhibition profile in a phase i, double-blind, single (SAD) and multiple ascending dose (MAD) study in healthy volunteers. (12th June 2018) Authors: Lickliter, J.; Bomba, D.; Anderl, J.; Fan, A.; Kirk, C.J.; Wang, J. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1413 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SAT0196 A DOUBLE BLIND, PLACEBO CONTROLLED, SINGLE ASCENDING DOSE (SAD) AND MULTIPLE ASCENDING DOSE (MAD) STUDY OF ALPN-101, A FIRST-IN-CLASS DUAL ICOS/CD28 ANTAGONIST, IN HEALTHY VOLUNTEERS (HV). (2nd June 2020) Authors: Yang, J.; Hillson, J.; Lickliter, J.; Manjarrez, K.; Tercero, A.; Wiley, J.; Means, G.; Sanderson, R.; Carley, K.; Peng, S. L. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 1040 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗